Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016622 · ClinicalTrials.gov registry record · Phase 2
Booster Dose Trial
A Phase 2 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT05016622: Clinical Trial Phase 2 study, sponsored by Montefiore Medical Center.
NCT05016622 is a Phase 2 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 106 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05016622, a Phase 2 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The goal of this study is to assess the safety and effectiveness of COVID vaccine booster doses in patients with cancer who have not developed an antibody after the U.S. Food and Drug Administration (FDA) Emergency Use Authorized COVID primary vaccination series.
Primary Outcome
Rate will be determined as the percentage of patients demonstrating booster-induced seroconversion, as evidenced by anti-Spike antibody testing, who were seronegative after the primary series of FDA authorized COVID-19 vaccinations.
Interventions
- BIOLOGICAL BNT162b2 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2023-05-21 |
| Phase | Phase 2 |
Why NCT05016622 stopped before completion
NCT05016622 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 1 intervention - of which BNT162b2 vaccine is the first listed.
NCT05016622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05016622 about?
NCT05016622 is a clinical study titled "Booster Dose Trial". The goal of this study is to assess the safety and effectiveness of COVID vaccine booster doses in patients with cancer who have not developed an antibody after the U.S. Food and Drug Administration (FDA) Emergency Use Authorized COVID primary vaccination series.
What is the current status of trial NCT05016622?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2021-08-10. Estimated completion is 2023-05-21.
What interventions are being tested in trial NCT05016622?
The interventions under investigation include: BNT162b2 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05016622?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05016622's enrollment target sits among peer trials
106 648th of 2000 higher than 1,351 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI